Please assess the completion status of the following clinical trial:

Trial Title: Docusate/Senna for the Treatment of Diabetic Gastroparesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-75 years, male and non-pregnant, non-lactating females~* Diagnosis of type 1 or type 2 diabetes mellitus~* Clinical diagnosis of diabetic gastroparesis~Exclusion Criteria:~* Diagnosed idiopathic gastroparesis~* A history or inflammatory bowel disease, such as Crohn's disease or ulcerative colitis~* A history of bowel obstruction, current unexplained abdominal pain, or undiagnosed rectal bleeding~* Gastrointestinal cancer~* Any active cancer~* Prior gastric surgery~* End-stage heart disease, liver disease, lung disease~* Known or suspected drug abuse~* Any condition requiring use of daily narcotics~* Concurrent usage of mineral oil or products containing mineral oil~* Current or recent (within the last 3 months) usage of Senokot-S, docusate or senna

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- High-dose (Type: EXPERIMENTAL): 8.6/50 mg of senna/docusate, oral, twice daily
- Low-dose (Type: EXPERIMENTAL): 8.6/50 mg of senna/docusate, oral, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).